Publications
Detailed Information
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Turner, N. C. | - |
dc.contributor.author | Finn, R. S. | - |
dc.contributor.author | Martin, M. | - |
dc.contributor.author | Im, S. -A | - |
dc.contributor.author | DeMichele, A. | - |
dc.contributor.author | Ettl, J. | - |
dc.contributor.author | Dieras, V. | - |
dc.contributor.author | Moulder, S. | - |
dc.contributor.author | Lipatov, O. | - |
dc.contributor.author | Colleoni, M. | - |
dc.contributor.author | Cristofanilli, M. | - |
dc.contributor.author | Lu, D. R. | - |
dc.contributor.author | Mori, A. | - |
dc.contributor.author | Giorgetti, C. | - |
dc.contributor.author | Iyer, S. | - |
dc.contributor.author | Bartlett, C. Huang | - |
dc.contributor.author | Gelmon, K. A. | - |
dc.date.accessioned | 2022-03-22T09:25:20Z | - |
dc.date.available | 2022-03-22T09:25:20Z | - |
dc.date.created | 2019-06-11 | - |
dc.date.created | 2019-06-11 | - |
dc.date.created | 2019-06-11 | - |
dc.date.created | 2019-06-11 | - |
dc.date.issued | 2018-03 | - |
dc.identifier.citation | Annals of Oncology, Vol.29 No.3, pp.669-680 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 75168 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177353 | - |
dc.description.abstract | This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral metastases. Pre- and postmenopausal women with disease progression following prior ET (PALOMA-3; N = 521) and postmenopausal women untreated for ABC (PALOMA-2; N = 666) were randomized 2 : 1 to ET (fulvestrant or letrozole, respectively) plus palbociclib or placebo. Progression-free survival (PFS), safety, and patient-reported quality of life (QoL) were evaluated by prior treatment and visceral involvement. Visceral metastases incidence was higher in patients with prior resistance to ET (58.3%, PALOMA-3) than in patients naive to ET in the ABC setting (48.6%, PALOMA-2). In patients with prior resistance to ET and visceral metastases, median PFS (mPFS) was 9.2 months with palbociclib plus fulvestrant versus 3.4 months with placebo plus fulvestrant [hazard ratio (HR), 0.47; 95% confidence interval (CI), 0.35-0.61], and objective response rate (ORR) was 28.0% versus 6.7%, respectively. In patients with nonvisceral metastases, mPFS was 16.6 versus 7.3 months, HR 0.53; 95% CI 0.36-0.77. In patients with visceral disease and naive to ET in the advanced disease setting, mPFS was 19.3 months with palbociclib plus letrozole versus 12.9 months with placebo plus letrozole (HR 0.63; 95% CI 0.47-0.85); ORR was 55.1% versus 40.0%; in patients with nonvisceral disease, mPFS was not reached with palbociclib plus letrozole versus 16.8 months with placebo plus letrozole (HR 0.50; 95% CI 0.36-0.70). In patients with prior resistance to ET with visceral metastases, palbociclib plus fulvestrant significantly delayed deterioration of QoL versus placebo plus fulvestrant, whereas patient-reported QoL was maintained with palbociclib plus letrozole in patients naive to endocrine-based therapy for ABC. Palbociclib plus ET prolonged mPFS in patients with visceral metastases, increased ORRs, and in patients previously treated for ABC, delayed QoL deterioration, presenting a standard treatment option among patients with visceral metastases amenable to endocrine-based therapy. NCT01942135, NCT01740427. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1093/annonc/mdx797 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000429455000023 | - |
dc.identifier.scopusid | 2-s2.0-85046082838 | - |
dc.citation.endpage | 680 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 669 | - |
dc.citation.volume | 29 | - |
dc.identifier.sci | 000429455000023 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, S. -A | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | DEPENDENT KINASE 4/6 | - |
dc.subject.keywordPlus | ENDOCRINE THERAPY | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | FULVESTRANT | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | LETROZOLE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | PALOMA-1/TRIO-18 | - |
dc.subject.keywordAuthor | palbociclib | - |
dc.subject.keywordAuthor | metastatic breast cancer | - |
dc.subject.keywordAuthor | advanced breast cancer | - |
dc.subject.keywordAuthor | visceral disease | - |
dc.subject.keywordAuthor | visceral metastases | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.